@article{951f346d4e844c1aadbc5b273608e5a7,
title = "074. LONG-TERM (UP TO 156 WEEKS) SAFETY PROFILE OF ORAL APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF PALACE 1–3",
author = "Mease, \{Philip J.\} and Gladman, \{Dafna D.\} and Gomez-Reino, \{Juan J.\} and Stephen Hall and Arthur Kavanaugh and Eric Lespessailles and Georg Schett and Maria Paris and Lichen Teng and Helena Marzo-Ortega and J{\"u}rgen Wollenhaupt",
note = "Background: The PALACE 1 (NCT01172938), 2 (NCT01212757), and 3 (NCT01212770) studies compared the efficacy and safety of apremilast (APR) with placebo in patients with active psoriatic arthritis despite prior conventional disease-modifying anti-rheumatic drugs and/or biologics. We assessed long-term APR safety for up to 3 years.",
year = "2017",
month = jan,
day = "4",
doi = "10.1093/rheumatology/kex062.074",
language = "American English",
volume = "56",
journal = "Rheumatology",
}